Aldevron’s Post

Advanced therapies are tailormade treatments and medicines, produced using an individual's tissue, genes or cells. They offer ground breaking opportunities to treat illness or injury, providing innovative care individual to each patient - known as personalised medicine. At Newcastle Hospitals we’re a leading centre for the implementation and delivery of advanced therapies. Our scientists, clinicians and researchers have strong expertise in the development and production of these products, which include CAR T-cell therapy. Our specialist in-house facilities and scientific expertise allows us to produce these medicines in a specialised, highly-regulated environment, before storage in liquid nitrogen on-site. An ‘early adopter’ of this life-saving treatment five years ago, our clinicians recently treated their 100th CAR T-cell patient. You can read more here https://lnkd.in/eQVAHvgQ #personalisedmedicine #advancedtherapies #genetherapies  #celltherapies #tissuetherapies Newcastle upon Tyne Hospitals commercial enterprise team Newcastle Health Innovation Partners (NHIP)

PhotoPharmics, Inc kickstarts phototherapy trial for #Parkinson’s disease: The Celeste #phototherapy device uses light to treat symptoms in Parkinson’s patients linked to the circadian system. S-based equipment manufacturer Photopharmics has announced the initiation of its ‘Celeste light for PD’ clinical trial investigating the Celeste phototherapy device.  The US Food and Drug Administration (FDA)-approved device targets photoreceptors in the eye responsible for circadian signalling. Research has shown that Parkinson’s disease can damage the retina and impact the circadian system leading to symptoms such as trouble sleeping, cognition, depression, and fatigue. https://lnkd.in/dk5wUfRV #Regulatorycompliance #RegulatoryStrategy

I've been involved in precision medicine care for a long time and to see the unfortunate number of patients benefit from biomarker positive results in aNSCLC (less than 35%) from this study, points to the work that still needs to be done in support of result utilization amongst treating clinicians. #biomarkertesting, #precisionmedicine, #patientadvocacy

Join us at ASH 2023 and explore ConcertAI's study on augmenting real-world mortality data in electronic medical records and its impact on survival estimates in Multiple Myeloma. Our research, spanning over a decade and involving 49,541 patients, reveals how integrating diverse data sources like EMRs, obituaries, and social security records can enhance the accuracy of overall survival estimates. Demonstrating the power of ConcertAI's data in providing more reliable and comprehensive insights, our findings pave the way for more informed treatment decisions and better patient outcomes in Multiple Myeloma and other hematologic malignancies. Discover more details about how we're transforming patient care in hematologic malignancies: https://lnkd.in/e43jmAt5 Pei Liu, Ziyu Lan, Brigham Walker, Gene Ray, & Helen Smith #ASH2023 #RealWorldData #OncologyInnovation #MultipleMyelomaResearch

Our global survey on acromegaly and #NETs treatment experiences was published in Advances in Therapy in August! 📚 Check out our paper on "Key Device Attributes for Injectable Somatostatin Receptor Ligand Therapy" to learn about crucial insights from patients, caregivers, and healthcare professionals. 💬 Here are some key takeaways: ◾Ease of use, safety, and less-burdensome injections are top priorities for patients and caregivers. ◾Importance of boosting confidence in administering injections for non-HCP caregivers and self-injecting patients. ◾Patient and caregiver input is vital for improving device design and fostering shared decision-making in treatment selection. Read more about the clinical insights and download the survey overview below! 📋 👉https://ow.ly/4hhi50QEYlk #MedEd

Exciting insights emerge from a study comparing the pharmacokinetic profiles of intravenous (IV) and subcutaneous (SC) immunoglobulin therapies, shedding light on their distinct immunomodulatory effects in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Understanding the differential responses to IV and SC immunoglobulins could revolutionize our approach to managing CIDP, empowering clinicians to tailor treatments for enhanced efficacy and patient outcomes. #CIDP #Immunotherapy #NeurologyResearch #MedicalScience #Healthcare #TreatmentOptimization NeurologyLive

A large-scale study out of the Cleveland Clinic, has demonstrated that Sildenafil (Viagra), a medication used for erectile dysfunction and pulmonary hypertension, can help protect brain cells from Alzheimer's disease. “Our findings provide further weight to re-purposing this existing FDA-approved drug as a novel treatment for Alzheimer’s, which is in great need of new therapies,” said Feixiong Cheng, Ph.D., who led the research. “We used artificial intelligence to integrate data across multiple domains which all indicated sildenafil’s potential against this devastating neurological disease.” #alzheimersdisease #dementiaresearch #alzheimersresearch #longtermcare #seniorcare #seniorliving #medicalresearch

Last year the REVIVED BCIS2 trial (https://lnkd.in/euC_gZdW) for patients with severe LV dysfunction, myocardial viability & PCI amenable coronary disease reported no improvement in LVEF at 12m, & no durable QALY improvement from PCI alone Now the health economic aspect is presented at AHA & published (https://lnkd.in/ewRsWbXG) - zero probability of PCI being cost effective in this group Will we be able to treat this cohort with more than heart failure medication? At Novo Nordisk, in partnership with HeartSeed, we are exploring the possibility of repairing the hearts of such patients via cell therapy. Watch this space for our progress ☺️

Diagnostic imaging relies heavily on intravenous iodinated contrast media (ICM) for crucial clinical insights. However, concerns about post-contrast acute kidney injury (PC-AKI), especially in patients with kidney issues, have caused hesitations. Clinical guidelines are vital in navigating these concerns, but their variability poses challenges. A review in Insights into Imaging evaluates existing guidelines on ICM use in kidney disease patients, uncovering areas of agreement and discord. It also suggests directions for future research and consensus-building efforts. Access the full story https://iii.hm/1qle #DiagnosticImaging #KidneyDisease

DID YOU KNOW? Kidney recipients account for about 60% of all organ #transplants in the U.S. Last August (2023), #VitaGraft Kidney received CMS coverage. VitaGraft Kidney, designed to identify signs of graft damage in patients with suspected rejection at least 12 days post-transplant, addresses a need in the transplant community. It offers a more precise and efficient method for assessing the risk of organ rejection. This could lead to earlier intervention and potentially improved transplant success rates. Additionally, VitaGraft might reduce the reliance on invasive biopsy procedures, enhancing patient comfort and safety. Oncocyte's CEO Josh Riggs, recently stated, "VitaGraft is supported by over a decade of published clinical data in kidney, liver and heart recipients. Our technology has repeatedly delivered reliable results with fast turnaround time, representing a significant improvement to the standard of care for at-risk patients and those under long-term management.“ This innovation not only benefits patients but also has the potential to optimize resource utilization in transplant medicine, making it a noteworthy development in improving transplant patient care and outcomes. #OCX #WhereTomorrowLives $OCX https://hubs.li/Q02gZDj80